awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q33435398-644C1A44-ACC9-4167-BB45-D40B683F1ADE
Q33435398-644C1A44-ACC9-4167-BB45-D40B683F1ADE
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33435398-644C1A44-ACC9-4167-BB45-D40B683F1ADE
A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis
P2860
Q33435398-644C1A44-ACC9-4167-BB45-D40B683F1ADE
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33435398-644C1A44-ACC9-4167-BB45-D40B683F1ADE
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
7ebbef791baf369dedcdaa6c5a9da42a997a9a1f
P2860
Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis.